Palivizumab is a humanized monoclonal antibody. It targets the fusion protein of respiratory syncytial virus (RSV) inhibiting its entry into the cell and thereby preventing infection. Palivizumab is therefore used in the prevention of RSV infections.
- INICIO
-
Genéricos
Novedades
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
- Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP
Investigación
- Re-evaluation of the use of generics, especially when treating conditions such as epilepsy
- La reutilización de medicamentos genéricos puede ahorrar tiempo y dinero
- Availability of medicines and the sustainable development of the national health system in Russia
- Generic etoricoxib is equivalent to the reference drug
-
Biosimilares
Novedades
- Nuevos biosimilares de adalimumab se preparan para su lanzamiento en Canadá, EE.UU. y Europa
- FDA approves Amneal’s bevacizumab biosimilar
- Europe: positive opinion for Inpremzia and Truvelog Mix 30 and Stimufend authorized
- FDA approves Kashiv Biosciences’ filgrastim biosimilar
Investigación
- Innovent and Eli Lilly announce final results for sintilimab plus biosimilar bevacizumab injection
- Biosimilar adoption and prescribing in Japan: a physician opinion survey
- Totality of evidence supporting approval of Avsola in the treatment of IBD
- Survey results of biosimilars use among Spanish physicians and pharmacists
- MORE EDITORIAL SECTIONS
- Search
Post your comment